4.2 Article

Reliability and validity of the Symptoms of Depression Questionnaire (SDQ)

Journal

CNS SPECTRUMS
Volume 19, Issue 6, Pages 535-546

Publisher

CAMBRIDGE UNIV PRESS
DOI: 10.1017/S1092852914000406

Keywords

anxious depression; assessment; depression

Funding

  1. Bristol- Myers Squibb, Co.
  2. Cerecor, Inc.
  3. Janssen Pharmaceutica
  4. Naurex, Inc.
  5. Pamlab, Inc.
  6. Ridge Diagnostics
  7. Shire Pic
  8. Takada Pharmaceuticals
  9. Novartis Pharmaceuticals
  10. Otsuka America
  11. Abbott Laboratories, Alkermes, Inc.
  12. American Cyanamid
  13. Aspect Medical Systems
  14. AstraZeneca
  15. BioResearch
  16. BrainCells Inc.
  17. Bristol- Myers Squibb
  18. CeNeRx BioPharma
  19. Cephalon
  20. Clintara, LLC
  21. Covance
  22. Covidien
  23. Eli Lilly and Company
  24. EnVivo Pharmaceuticals, Inc.
  25. Euthymics Bioscience, Inc.
  26. Forest Pharmaceuticals, Inc.
  27. Ganeden Biotech, Inc
  28. GlaxoSmithKline
  29. Harvard Clinical Research Institute
  30. Hoffman-LaRoche
  31. Icon Clinical Research
  32. i3 Innovus/Ingenix
  33. Janssen RD, LLC
  34. Jed Foundation
  35. Johnson & Johnson Pharmaceutical Research Development
  36. Lichtwer Pharma GmbH
  37. Lorex Pharmaceuticals
  38. MedAvante
  39. National Alliance for Research on Schizophrenia & Depression (NARSAD)
  40. National Institute of Drug Abuse (NIDA)
  41. National Institute of Mental Health (NIMH)
  42. Neuralstem, Inc.
  43. Novartis AG
  44. Organon Pharmaceuticals
  45. PamLab, LLC
  46. Pfizer Inc.
  47. Pharmacia-Upjohn, Pharmaceutical Research Associates, Inc.
  48. Pharmavite(R) LLC
  49. PharmoRx Therapeutics
  50. Photothera
  51. Roche Pharmaceuticals
  52. RCT Logic, Inc.
  53. Clinical Trials Solutions, LLC
  54. Sanofi-Aventis US LLC
  55. Shire
  56. Solvay Pharmaceuticals, Inc., Synthelabo
  57. Wyeth-Ayerst Laboratories

Ask authors/readers for more resources

Current measures for major depressive disorder focus primarily on the assessment of depressive symptoms, while often omitting other common features. However, the presence of comorbid features in the anxiety spectrum influences outcome and may effect treatment. More comprehensive measures of depression are needed that include the assessment of symptoms in the anxiety-depression spectrum. This study examines the reliability and validity of the Symptoms of Depression Questionnaire (SDQ), which assesses irritability, anger attacks, and anxiety symptoms together with the commonly considered symptoms of depression. Analysis of the factor structure of the SDQ identified 5 subscales, including one in the anxiety-depression spectrum, with adequate internal consistency and concurrent validity. The SDQ may be a valuable new tool to better characterize depression and identify and administer more targeted interventions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available